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Role of antimalarials in COVID-19: observational 
data from a cohort of rheumatic patients
The potential role of chloroquine (CQ) and hydroxychloro-
quine (HCQ) in the management of COVID-19 is certainly of 
relevance in this health emergency scenario. For this reason, 
we read with great interest the letter published by Romão and 
colleagues highlighting the need for more definite evidence on 
the role of antimalarial drugs in both preventing severe acute 
respiratory syndrome coronavirus-2 infection and making 
COVID-19 clinical course milder.1 While several ongoing 
clinical trials are progressively providing controversial data 
about the real efficacy and safety of antimalarials in the treat-
ment of overt COVID-19,2–4 rheumatological patients already 
taking CQ or HCQ for the treatment of chronic inflammatory 
diseases are an excellent bench for testing the potential effect 
in preventing the contagion.5 Being operative in the Research 
Center for Adult and Paediatric Rheumatic Diseases of the 
ASST Gaetano Pini- CTO in Milan (Lombardy), we had the 
opportunity to deal with a large cohort of rheumatic patients 
living in one of the regions most affected by the outbreak.6 
In the period between 25 February and 16 April 2020 we 
circulated among our patients a survey designed to investigate 
the incidence of COVID-19 (defined as nasopharyngeal swab 
positivity) and symptoms consistent with viral infection, and 
to clarify how our patients had changed their treatment and 
behaviour due to the outbreak. The survey was administered 
face- to- face to all patients evaluated during an outpatient visit 
or by telephone to those who missed a scheduled appointment 
during the period under review. The rate of non- responders to 
the survey was very low (1.85%) and unlikely to significantly 
affect the overall results. The final study population included 
914 patients stratified in HCQ- users (n=112) and non- HCQ- 
users (n=802), whose demographic and clinical characteris-
tics are detailed in table 1. Briefly, mean age, mean disease 
duration and prevalence of comorbidity were overlapping 
in the two groups. Conversely, significant differences were 
observed in the distribution according to gender (female prev-
alence was greater in HCQ- users) and diagnosis (rheumatoid 
arthritis and connective tissue diseases were more frequent in 
HCQ- users, whereas spondyloarthritis in non- HCQ- users). 
Moreover, the prevalence of concomitant biological/targeted 
synthetic drugs was higher in non HCQ- users, while cortico-
steroids were more frequently reported in HCQ- users. The 
vast majority of patients in both groups had strictly adhered 
to the norms for the prevention of contagion (use of masks 
and gloves, social distancing, home- working) since the begin-
ning of the epidemic. The frequency of definite contact with 
COVID-19 positive subjects was similar in both groups. In 
the overall population, six patients with COVID-19 positive 
swab were observed, five of whom had a complete recovery 
(four required hospitalisation with low- flow oxygen therapy), 
while a 32- year- old woman suffering from systemic sclerosis 
with lung involvement (taking HCQ) died. The incidence of 
COVID-19 positive subjects was comparable in the two groups 
(0.89% in HCQ- users vs 0.62% in non HCQ- users; p=0.64). 
This result did not change either by broadening the defini-
tion of COVID-19 to include patients who had not had access 
to the swab but who presented symptoms consistent with 
COVID-19 (at least one between fever >37.5°C, cough, or 
dyspnoea of recent onset), or were living in a highly endemic 
area (COVID-19 incidence ≥1%), according to WHO criteria 
(16% HCQ users vs 14.6% non- users; p=0.67). In conclusion, 
our preliminary data does not appear to support the use of 
antimalarials as prophylactic therapy for COVID-19, although 
the lack of a complete matching between the two groups under 
analysis does not allow definitive conclusions to be drawn.
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Table 1 Demographic and clinical characteristics of study 
population
HCQ users
(n=112)
Non- HCQ users
(n=802) P value
Age (mean±SD) 57.3±14.2 54.5±16 0.06
Female 96 (85.7%) 528 (65.8%) <0.0001
Disease duration (mean±SD) 11.4±10 13.4±9 0.07
Diagnosis     
  Rheumatoid arthritis 79 (70.6%) 401 (50%) <0.0001
  Spondyloarthritis 8 (7.1%) 307 (38.2%) <0.0001
  Connective tissue diseases 21 (18.7%) 52 (6.5%) <0.0001
  Other 4 (3.6%) 42 (5.3%) 0.64
Concomitant bDMARD 50 (44.6%) 605 (75.4%) <0.0001
Concomitant corticosteroids 70 (62.5%) 253 (31.5%) <0.0001
Comorbidities (≥1) 39 (34.8%) 302 (37.6%) 0.60
COVID-19     
  Contagion prevention 93 (83%) 700 (87.2%) 0.23
  Treatment discontinuation 4 (3.6%) 42 (5.2%) 0.54
  Definite contact with COVID-19 
positive subjects
2 (1.8%) 14 (1.7%) 0.90
  COVID-19 positive swab 1 (0.89%) 5 (0.62%) 0.64
  Respiratory symptoms (no swab) 18 (16%) 117 (14.6%) 0.67
P value was calculated by using Fisher’s test for categorical variables and t- test for 
continuous variables. Respiratory symptoms, at least one between fever >37.5°C, cough, or 
dyspnoea of recent onset.
bDMARD, biologic disease- modifying antirheumatic drugs; HCQ, hydroxychloroquine.
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